A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @GeneticCouns: A recent @nresearchnews paper models the cost effectiveness of cascade testing for dilated cardiomyopathy in Australia, c…

RT @GeneticCouns: A recent @nresearchnews paper models the cost effectiveness of cascade testing for dilated cardiomyopathy in Australia, c…

A recent @nresearchnews paper models the cost effectiveness of cascade testing for dilated cardiomyopathy in Australia, contributing valuable health economic data to support the role of genetic counseling services: https://t.co/b7ztB5RGSK #GCChat

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

Cascade genetic testing cost effective in families of patients with suspected heritable dilated cardiomyopathy. https://t.co/oTS0GWQyDv

RT @MarcosCicerchia: | Using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with DCM is very…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @MarcosCicerchia: | Using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with DCM is very…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @GIMJournal: Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess…

RT @MarcosCicerchia: | Using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with DCM is very…

| Using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with DCM is very likely to be cost-effective. | #DCM #cardiomyopathies #cardio #Genetics in Medicine https://t.co/WgM3oNDucb

Cascade genetic testing is likely cost-effective for asymptomatic relatives of dilated cardiomyopathy patients #openaccess #CardioGen https://t.co/UkEHXdtvUv https://t.co/MBiWLhCTxC

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

RT @DrJRamchand: Our work on cost-effectiveness of genetic testing in dilated cardiomyopathy. Great collaborative effort involving @MelbGen…

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

RT @jodieingles27: The addition of genetic testing to management of #DCM families is cost-effective. Nice study from some fellow Aussies! @…

We already knew this for #HCM... Nice to see the same in #DCM!!! "#Genetic testing to guide clinical surveillance of asymptomatic relatives [...] Is very likely to be cost-effective" https://t.co/Bze6InKhqX

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

RT @DrJRamchand: Our work on cost-effectiveness of genetic testing in dilated cardiomyopathy. Great collaborative effort involving @MelbGen…

RT @MelbGenomics: Using cascade genetic testing for asymptomatic relatives of patients with dilated cardiomyopathy is cost effective @GIMJo…

RT @jodieingles27: The addition of genetic testing to management of #DCM families is cost-effective. Nice study from some fellow Aussies! @…

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

RT @DrJRamchand: Our work on cost-effectiveness of genetic testing in dilated cardiomyopathy. Great collaborative effort involving @MelbGen…

RT @MaxCatchpool: We found that using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with dil…

RT @MaxCatchpool: We found that using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with dil…

RT @MaxCatchpool: We found that using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with dil…

We found that using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with dilated cardiomyopathy is likely to be cost-effective. Great to get this published with @IliasGoranitis @DrJRamchand @MelbGenomics https:/

RT @MelbGenomics: Using cascade genetic testing for asymptomatic relatives of patients with dilated cardiomyopathy is cost effective @GIMJo…

Using cascade genetic testing for asymptomatic relatives of patients with dilated cardiomyopathy is cost effective @GIMJournal. Congratulations to everyone who worked on this paper: https://t.co/QdKX3Hg6lG @MaxCatchpool @DrJRamchand @mmartyn8 @IliasGoranit

RT @DrJRamchand: Our work on cost-effectiveness of genetic testing in dilated cardiomyopathy. Great collaborative effort involving @MelbGen…

Our work on cost-effectiveness of genetic testing in dilated cardiomyopathy. Great collaborative effort involving @MelbGenomics and @HEU_unimelb https://t.co/Vl6KrfS5ut

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

RT @IliasGoranitis: Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Gre…

The addition of genetic testing to management of #DCM families is cost-effective. Nice study from some fellow Aussies! @IliasGoranitis @DrJRamchand #cardiogen @GIMJournal @AusGenomics

What's the cost-effectiveness of cascade screening in the evaluation and management of families with dilated cardiomyopathy? Promising decision-analytic model. Via @GIMJournal https://t.co/61Eigo5o4K https://t.co/5M3oKAkIVL

Cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy is highly cost-effective. Great to see this paper led by @MaxCatchpool in @GIMJournal. More info here: https://t.co/afPzbZ2RVl @MelbGenomics @AusGenomics @HEU_unimelb